117.54
-3.47 (-2.87%)
| Previous Close | 121.01 |
| Open | 121.48 |
| Volume | 1,430,236 |
| Avg. Volume (3M) | 838,220 |
| Market Cap | 6,798,713,344 |
| Price / Earnings (Forward) | 81.30 |
| Price / Sales | 11.54 |
| Price / Book | 3.79 |
| 52 Weeks Range | |
| Earnings Date | 28 Jul 2025 - 1 Aug 2025 |
| Profit Margin | -3.53% |
| Operating Margin (TTM) | 5.59% |
| Diluted EPS (TTM) | -0.420 |
| Quarterly Revenue Growth (YOY) | 10.40% |
| Quarterly Earnings Growth (YOY) | 76.90% |
| Total Debt/Equity (MRQ) | 34.44% |
| Current Ratio (MRQ) | 6.79 |
| Operating Cash Flow (TTM) | 145.69 M |
| Levered Free Cash Flow (TTM) | 183.66 M |
| Return on Assets (TTM) | 0.92% |
| Return on Equity (TTM) | -1.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bearish | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | Repligen Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.25 |
|
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 6.41% |
| % Held by Institutions | 105.18% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 190.00 (JP Morgan, 61.65%) | Buy |
| Median | 180.00 (53.14%) | |
| Low | 130.00 (Evercore ISI Group, 10.60%) | Hold |
| Average | 167.80 (42.76%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 134.05 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 08 Jul 2025 | 130.00 (10.60%) | Hold | 128.56 |
| Barclays | 24 Jun 2025 | 150.00 (27.62%) | Buy | 123.35 |
| HC Wainwright & Co. | 05 May 2025 | 180.00 (53.14%) | Buy | 140.92 |
| RBC Capital | 30 Apr 2025 | 189.00 (60.80%) | Buy | 137.99 |
| JP Morgan | 29 Apr 2025 | 190.00 (61.65%) | Buy | 139.43 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 17 Jul 2025 | Announcement | Repligen to Report Second Quarter 2025 Financial Results |
| 16 Jun 2025 | Announcement | 908 Devices Appoints Christopher D. Brown to its Board of Directors |
| 22 May 2025 | Announcement | Repligen Corporation to Present at William Blair Growth Conference |
| 07 May 2025 | Announcement | Repligen Corporation to Present at Upcoming May Investor Conferences |
| 29 Apr 2025 | Announcement | Repligen Reports First Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |